Addepalli V.,Narsee Monjee Institute of Management and Higher Studies |
Bafna P.A.,Pad Dr Dy Patil Institute Of Pharmaceutical Science And Research |
Prabhavalkar K.S.,Narsee Monjee Institute of Management and Higher Studies
Journal of Experimental and Clinical Medicine | Year: 2010
Depressed patients receiving antidepressant treatment for therapeutic purpose also consume caffeine in the form of tea or coffee drinks as a part of their daily life. These depressed patients seek a " lift" because of fatigue or negative affect, thereby consuming high amount of caffeine as a self-medication to increase alertness. This further may lead to increased negative affect and depressive symptoms. Unfortunately, many studies evaluating caffeine in youth have considered samples belonging to either moderate or higher level of caffeine intake. Caffeine, as a psychomotor stimulant, is known to inhibit the pre- and postsynaptic brakes imposed by adenosine on dopaminergic neurotransmission. Evidences also indicate an important role of caffeine as an adenosine receptor blocker in depression treatment. Caffeine may help in the treatment of chronic depression by potentiating dopaminergic system. Antidepressant agents are known to normalize depressed mood by influencing a variety of neurotransmitter systems including dopamine. Evidences suggest a possible positive effect on dopaminergic activity of caffeine augmentation (10 mg/kg or lower dose) with antidepressant agents for depression treatment. These findings suggest a need of considering and future evaluation of possible beneficial effects of low dose of caffeine augmentation with antidepressants in depressed patients. © 2010.
Wankhede S.B.,Pad Dr Dy Patil Institute Of Pharmaceutical Science And Research |
Somani K.,Pad Dr Dy Patil Institute Of Pharmaceutical Science And Research |
Chitlange S.S.,Pad Dr Dy Patil Institute Of Pharmaceutical Science And Research
International Journal of ChemTech Research | Year: 2011
This paper presents the development and validation of normal phase HPTLC methods for simultaneous analysis of afluzosin and solifenacin in tablets. Chromatography was performed on silica gel 60F 254 plate as stationary phase and the mobile phase comprised of methanol: ethyl acetate (7:3, v/v). Detection wavelengths selected were 254 nm for Alfuzosin and 220 nm for solifenacin. The Rf values were 0.71 ± 0.03 and 0.32± 0.02 for Alfuzosin and solifenacin, respectively. A TLC scanner set at 254 nm and 220 nm for Alfuzosin and Solifenacin, respectively was used for direct evaluation of the chromatograms in reflectance/absorbance mode. Method was validated according to ICH guidelines. Determination coefficients of calibration curves were found 0.9903 and 0.9981 in the concentration ranges 500-2500 ng/band for Alfuzosin and solifenacin, respectively. Method had an accuracy of 99.30 % for Alfuzosin and 98.91 % for solifenacin. Both the HPTLC methods had the potential to determine these drugs from dosage forms without any interference.
Chitlange S.S.,Pad Dr Dy Patil Institute Of Pharmaceutical Science And Research |
Soni R.,Pad Dr Dy Patil Institute Of Pharmaceutical Science And Research
Journal of Chemical and Pharmaceutical Sciences | Year: 2010
The present work describes a stability-indicating HPTLC method for analysis of paracetamol and dexibuprofen in bulk and pharmaceutical dosage form. Precoated silica gel 60 F 254 plate was used as stationary phase. The separation was carried out using n-hexane: ethyl acetate: glacial acetic acid (5: 5: 0.2 %v/v/v) as mobile phase. The densitometric scanning was carried out at 223 nm. The linearity was obtained in the range 10-50 μg/band for paracetamol and 6-30 μg/band for dexibuprofen with correlation coefficients (r 2) 0.9915 and 0.9969 for paracetamol and dexibuprofen respectively. The method was validated as per ICH guidelines. The combination was subjected to forced degradation by acid, alkali, oxidation and dry heat. The degradation products were well resolved from the pure drug with significantly different R f values.